CLERICO, Marinella
CLERICO, Marinella
SCIENZE CLINICHE E BIOLOGICHE
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b
2006-01-01 A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b
2006-01-01 A. RICCI; A. CUCCI; A. ROVERA; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
A COCHRANE meta-analysis on the efficacy of recombinant interferon beta in preventing conversion of clinically isolated syndromes
2006-01-01 M. CLERICO; F. FAGGIANO; J. PALACE; M. TINTOR; G. RICE; L. DURELLI
A COCHRANE review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to Multiple Sclerosis
2006-01-01 M. CLERICO; M. TINTORE' SUBIRANA; J. PALACE; G. RICE; F. FAGGIANO; L. DURELLI
A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study.
2004-01-01 E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; L. GIORDANO; L. DURELLI
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients.
2011-01-01 Simona Rolla; Valentina Bardina; Marinella Clerico; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli
A Real-Life Study of Alemtuzumab: Impact of Previous Therapies and Washout Period on Disease Activity
2018-01-01 Sacca, F; Sormani, MP; Signori, A; Lanzillo, R; Baroncini, D; Annovazzi, P; Signoriello, E; Laroni, A; Capobianco, M; Sartori, A; La Gioia, S; Maniscalco, GT; Cordioli, C; Rasia, S; Clerico, M; Fenu, G; Cocco, E; Frau, J
A real-world study of Alemtuzumab in a cohort of Italian patients
2019-01-01 Sacca, F; Russo, CV; Frau, J; Annovazzi, P; Signoriello, E; Bonavita, S; Grasso, R; Clerico, M; Cordioli, C; Laroni, A; Capobianco, M; Clerici, VT; Sartori, A; Cavalla, P; Maniscalco, GT; La Gioia, S; Caleri, F; Giugno, A; Iodice, R; Carotenuto, A; Cocco, E; Fenu, G; Zaffaroni, M; Baronicini, D; Lus, G; Gallo, A; De Mercanti, SF; Lapucci, C; Di Francescantonio, V; Sormani, MP; Signori, A
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months
2016-01-01 Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation
2016-01-01 Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials
2012-01-01 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L.
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study
2018-01-01 Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Via, AG; Lamberti, A; Lanzillo, R; Bonavita, S; Esposito, S; Giordano, M; Cocolin, LS; Clerico, M
ALTERATIONS IN GUT MICROBIOME COMPOSITION ARE ASSOCIATED WITH THE ONSET AND COURSE OF MULTIPLE SCLEROSIS: AN ITALIAN COHORT STUDY
2023-01-01 Rachele Rosso, Alessandro Maglione, Marinella Clerico, Simona Rolla
Anti-interferon neutralising antibody occurrence in relapsing remitting ms patients treated with a ifn beta-1b dose higher than the standard one: long-term evaluation
2005-01-01 A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; M. CLERICO; B. FERRERO; A. ROVERA; L. GIORDANO; G. CONTESSA; E. FESTA; L. DURELLI; ON BEHALF OF THE OPTIMS TRIAL STUDY GROUP
Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD).
2003-01-01 M. CLERICO; E. ROTA; A. RICCI; E. VERDUN; P. BARBERO; A. PIPIERI; A. CUCCI; L. GIORDANO; L. DURELLI
Are arterial hypertension and diabetes modifiers of ALS phenotype and outcome? A population-based study
2015-01-01 Calvo, A; Moglia, C; Canosa, A; Bertuzzo, D; Galmozzi, F; Cugnasco, P; Clerico, M; De Mercanti, S; Bersano, E; Cammarosano, S; Ilardi, A; Manera, U; Sideri, R; Marinou, K; Bottacchi, E; Pisano, F; Cantello, R; Mazzini, L; Mora, G; Chiò, A
Assessing treatment response to immunomodulatory drugs for ms: a single active mri scan after 6 months of treatment is the best indicator of persisting disease activity
2005-01-01 L. DURELLI; E. VERDUN; P. BARBERO; M. CLERICO; B. FERRERO; E. VERSINO; G. GIULIANI; E. MONTANARI; THE OPTIMS STUDY GROUP
Atypical Presentation of Progressive Multifocal Leukoencephalopathy in a Natalizumab-treated Patient
2015-01-01 De Mercanti, S; Artusi, Ca; Clerico, M; Iudicello, M; Vacca, A; Virgilio, E; Durelli, L
Atypical presentation of superficial sclerosis successfully treated with iron chelation
2013-01-01 De Mercanti S; Iudicello M; Clerico M; Piazza F; Gibbin M; Longo F; Durelli L
Autoimmunity profile in interferon beta- 1a treated Multiple Sclerosis patients. the auprin study: comparison of 2 different dosage of subcutaneous interferon-beta 1a
2005-01-01 E. VERDUN; L. GIORDANO; M.A. CUCCI; A. RICCI; P. BARBERO; A. PIPIERI; M. CLERICO; G. AIMO; L. DURELLI; THE AUPRIN STUDY GROUP
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b | 2006 | A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP | |
| A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b | 2006 | A. RICCI; A. CUCCI; A. ROVERA; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP | |
| A COCHRANE meta-analysis on the efficacy of recombinant interferon beta in preventing conversion of clinically isolated syndromes | 2006 | M. CLERICO; F. FAGGIANO; J. PALACE; M. TINTOR; G. RICE; L. DURELLI | |
| A COCHRANE review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to Multiple Sclerosis | 2006 | M. CLERICO; M. TINTORE' SUBIRANA; J. PALACE; G. RICE; F. FAGGIANO; L. DURELLI | |
| A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study. | 2004 | E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; L. GIORDANO; L. DURELLI | |
| A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. | 2011 | Simona Rolla; Valentina Bardina; Marinella Clerico; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli | |
| A Real-Life Study of Alemtuzumab: Impact of Previous Therapies and Washout Period on Disease Activity | 2018 | Sacca, F; Sormani, MP; Signori, A; Lanzillo, R; Baroncini, D; Annovazzi, P; Signoriello, E; Laroni, A; Capobianco, M; Sartori, A; La Gioia, S; Maniscalco, GT; Cordioli, C; Rasia, S; Clerico, M; Fenu, G; Cocco, E; Frau, J | |
| A real-world study of Alemtuzumab in a cohort of Italian patients | 2019 | Sacca, F; Russo, CV; Frau, J; Annovazzi, P; Signoriello, E; Bonavita, S; Grasso, R; Clerico, M; Cordioli, C; Laroni, A; Capobianco, M; Clerici, VT; Sartori, A; Cavalla, P; Maniscalco, GT; La Gioia, S; Caleri, F; Giugno, A; Iodice, R; Carotenuto, A; Cocco, E; Fenu, G; Zaffaroni, M; Baronicini, D; Lus, G; Gallo, A; De Mercanti, SF; Lapucci, C; Di Francescantonio, V; Sormani, MP; Signori, A | |
| Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months | 2016 | Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M | |
| Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation | 2016 | Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M | |
| Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials | 2012 | De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L. | |
| Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study | 2018 | Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Via, AG; Lamberti, A; Lanzillo, R; Bonavita, S; Esposito, S; Giordano, M; Cocolin, LS; Clerico, M | |
| ALTERATIONS IN GUT MICROBIOME COMPOSITION ARE ASSOCIATED WITH THE ONSET AND COURSE OF MULTIPLE SCLEROSIS: AN ITALIAN COHORT STUDY | 2023 | Rachele Rosso, Alessandro Maglione, Marinella Clerico, Simona Rolla | |
| Anti-interferon neutralising antibody occurrence in relapsing remitting ms patients treated with a ifn beta-1b dose higher than the standard one: long-term evaluation | 2005 | A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; M. CLERICO; B. FERRERO; A. ROVERA; L. GIORDANO; G. CONTESSA; E. FESTA; L. DURELLI; ON BEHALF OF THE OPTIMS TRIAL STUDY GROUP | |
| Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD). | 2003 | M. CLERICO; E. ROTA; A. RICCI; E. VERDUN; P. BARBERO; A. PIPIERI; A. CUCCI; L. GIORDANO; L. DURELLI | |
| Are arterial hypertension and diabetes modifiers of ALS phenotype and outcome? A population-based study | 2015 | Calvo, A; Moglia, C; Canosa, A; Bertuzzo, D; Galmozzi, F; Cugnasco, P; Clerico, M; De Mercanti, S; Bersano, E; Cammarosano, S; Ilardi, A; Manera, U; Sideri, R; Marinou, K; Bottacchi, E; Pisano, F; Cantello, R; Mazzini, L; Mora, G; Chiò, A | |
| Assessing treatment response to immunomodulatory drugs for ms: a single active mri scan after 6 months of treatment is the best indicator of persisting disease activity | 2005 | L. DURELLI; E. VERDUN; P. BARBERO; M. CLERICO; B. FERRERO; E. VERSINO; G. GIULIANI; E. MONTANARI; THE OPTIMS STUDY GROUP | |
| Atypical Presentation of Progressive Multifocal Leukoencephalopathy in a Natalizumab-treated Patient | 2015 | De Mercanti, S; Artusi, Ca; Clerico, M; Iudicello, M; Vacca, A; Virgilio, E; Durelli, L | |
| Atypical presentation of superficial sclerosis successfully treated with iron chelation | 2013 | De Mercanti S; Iudicello M; Clerico M; Piazza F; Gibbin M; Longo F; Durelli L | |
| Autoimmunity profile in interferon beta- 1a treated Multiple Sclerosis patients. the auprin study: comparison of 2 different dosage of subcutaneous interferon-beta 1a | 2005 | E. VERDUN; L. GIORDANO; M.A. CUCCI; A. RICCI; P. BARBERO; A. PIPIERI; M. CLERICO; G. AIMO; L. DURELLI; THE AUPRIN STUDY GROUP |